Psoriasis Pipeline Heats Up: New Clinical Trial Data Signals Investment Opportunities

NEW YORK, NY – November 14, 2025

Global Clinical Trials Fuel Innovation

A comprehensive new report analyzing global clinical trials for plaque psoriasis is providing valuable insights for pharmaceutical companies, investors, and healthcare professionals. The “Plaque Psoriasis (Psoriasis Vulgaris) - Global Clinical Trials Review, 2025,” from Research and Markets, details the current landscape of clinical development, with data spanning trials in G7 and E7 countries. The analysis covers trial phases, sponsor types, enrollment numbers, and endpoint status, offering a granular view of a rapidly evolving therapeutic area. The report underscores a robust pipeline, fueled by both innovative biologic therapies and the increasing presence of biosimilars.

“We’re seeing a significant surge in late-stage trials, particularly for oral therapies,” explained one industry analyst. “This indicates a move towards more convenient treatment options for patients, which is a key unmet need.” The analyst emphasized that this shift is attracting considerable investment from both established pharmaceutical giants and emerging biotechnology firms.

Investment Landscape and Market Growth

The global psoriasis treatment market is poised for substantial growth, with projections ranging from $20.52 billion in 2024 to over $57 billion by 2032, representing a compound annual growth rate (CAGR) of approximately 10%. Key drivers include the rising prevalence of psoriasis, increasing awareness of available treatment options, and advancements in targeted therapies. The market is currently dominated by biologic drugs, such as IL-17 and IL-23 inhibitors, but a growing number of oral small molecule therapies are entering the pipeline, offering a potential alternative for patients who may not respond to, or prefer to avoid, injectable treatments.

Investment is flowing into companies developing these innovative therapies, as well as those focused on biosimilar development. Biosimilars are becoming increasingly important in driving down healthcare costs and expanding access to treatment, particularly in emerging markets. The approval of ustekinumab biosimilars earlier this year demonstrates the growing acceptance of these cost-effective alternatives. “The biosimilar space is very competitive,” noted a pharmaceutical executive. “Companies are looking for opportunities to differentiate themselves through manufacturing efficiencies and expanded product offerings.”

Emerging Trends and Pipeline Highlights

The psoriasis treatment pipeline is characterized by a diverse range of therapeutic approaches. Beyond traditional biologic therapies, companies are exploring novel targets, such as TYK2 and S1P receptors, and investigating innovative modalities, including gene editing and microbiome modulation. Several late-stage trials are currently underway, evaluating the efficacy and safety of these promising new therapies.

Notable pipeline highlights include icotrokinra, a potential first-in-class oral IL-23 inhibitor from Johnson & Johnson, which recently submitted an FDA application for approval. Several other companies are also advancing oral small molecule therapies, including Alumis, with its TYK2 inhibitor ESK-001, and Sun Pharmaceutical, with its S1P receptor modulator. In addition, several companies are focused on developing biosimilars to existing biologic therapies, offering a more affordable treatment option for patients.

Recent regulatory approvals have also shaped the landscape. The FDA approval of roflumilast topical foam for plaque psoriasis, and expanded indications for drugs like guselkumab, demonstrate continued innovation and a commitment to addressing unmet patient needs. “We’re seeing a trend towards personalized medicine, with companies developing biomarkers to identify patients who are most likely to respond to specific treatments,” explained a clinical researcher. “This will ultimately lead to more effective and targeted therapies.”

Geographic Focus and Emerging Markets

While North America currently holds the largest share of the psoriasis treatment market, the Asia-Pacific region is expected to experience the fastest growth in the coming years. This is driven by factors such as increasing awareness of psoriasis, rising disposable incomes, and improving access to healthcare. Several companies are expanding their presence in the Asia-Pacific region, through strategic partnerships, acquisitions, and direct investment.

“Emerging markets represent a significant opportunity for growth,” noted a market analyst. “However, companies need to be mindful of the unique challenges in these markets, such as pricing pressures, regulatory hurdles, and cultural differences.” The report from Research and Markets highlights the importance of understanding these local dynamics when developing market entry strategies.